Perioperative Care of the Immunocompromised Patient

Acute Care of the Cancer Patient

Volumn , Issue , 2005, Pages 217-230

  Peake, Sandra L ^a   Ghelani, Dhaval R ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247858735     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Mackall CL, Fleisher TA. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221-2226.
2. Yaniv I, Danon YL. Immune reconstitution after chemotherapy for malignant solid tumours in children. Pediatr Hematol Oncol 1994; 11:1-6.
3. Udit NV, Mazumdar A. Immune reconstitution following bone marrow transplantation. Cancer Immunol Immunother 1993; 37:351-355.
4. Alanko S, Pelliniemi T. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 1992; 1481-1486.
5. Mustafa MM, Buchanan GR. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 1998; 20:451-457.
6. Mathes DD, Bogdonff DL. Preoperative evaluation of the cancer patient. In: Lefor AT, ed. Surgical Problems Affecting Patient with Cancer. Philadelphia: Lippincott-Rave, 1996:273-304.
7. Billingham ME, Mason JW, Bristow MR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62:865-872.
8. Shaw IH, Kirk AJB, Conacher ID. Anaesthesia for patients with transplanted hearts and lungs undergoing non-cardiac surgery. Br J Anaesth 1991; 67:772-778.
9. George SJ, Vuddamalay P, Boscoe MJ. Antisepticimpregnated central venous catheters reduce the incidence of bacterial colonisation and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol 1997; 14:428-431.
10. Reissell E, Orko R, Manuksela E-L, Lindgren L. Predictability of difficult laryngoscopy in patients with long-term diabetes mellitus. Anaesthesia 1990; 45:1024-1027.
11. Ruutu T. Bone marrow transplantation. Ann Chir Gynaecol 1997; 86:127-137.
12. Sharpe MD. Anesthesia and the transplanted patient. Can J Anaesth 1996; 43:R89-R93.
13. Boscoe M. Anesthesia for patients with transplanted heart and lungs. Int Anesthesiol Clin 1995; 33:21-44.
14. Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation Part I. Am Rev Respir Dis 1991; 143:1386-1405.
15. Haddow GTR, Brock-Utne JG. A non-thoracic operation for a patient with single transplantation. Acta Anaesthesiol Scand 1999; 43:960-963.
16. Ramus GV, Cesano L, Barbalonga A. Different concentrations of local anaesthetics have different modes of action on human lymphocytes. Agents Actions 1983; 13:333-341.
17. Sinciair R, Eriksson AS, Gretzer G, Cassuto J, Thomsen P. Inhibitory effects of amide local anaesthetics on stimulus-induced human leucocyte metabolic activation. LTB4 release and ZL-1 secretion in vitro. Acta Anaesthesiol Scand. 1983; 37:159-165.
18. Salo M. Effects of lignocaine and bupivacaine on immunoglobulin synthesis in vitro. Eur J Anaesthesiol 1990; 7:133-135.
19. Tonneson E, Wahlgreen C. Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth 1998; 73:315-317.
20. Hashimoto T, Hashimoto S, Hon Y. Epidural anaesthesia blocks changes in peripheral lymphocyte subpopulation gastrectomy for stomach cancer. Acta Anaesthesiol Scand 1995; 39:294-298.
21. Hole A, Unsgaard G, Bseink H. Monocyte functions are depressed during and after surgery under general anaesthesia but not under epidural anaesthesia. Acta Anaesthesiol Scand 1982; 26:301-307.
22. Woods GM, Griffiths DM. Reversible inhibition of NK cell activity by volatile anaesthetic agents in vitro. Br J Anaesth 1986; 58:53-59.
23. 2O on human leucocyte chemotaxis in vitro. Can Anaesth Soc J 1984; 31:631-637.
24. Rossano F, Tufano R, Cipollaro de L’Ero. Anaesthetic agents induce human mononuclear leucocytes to release cytokines. Immunopharmacol Immunotoxicol 1992; 14:439-450.
25. Pirttikangas C-O, Pertilla J, Salo M. Propofol emulsion reduces proliferative responses of lymphocytes from intensive care patients. Intensive Care Med 1993; 19:299-302.
26. Larsen B, Hoff G, Wilhelm W, Buchinger H, Wanner G, Bauer M. Effect of intravenous anaesthetics on spontaneous and endotoxin stimulated cytokine response in cultured human whole blood. Anaesthesiology 1998; 89:1218-1222.
27. Jensen AG, Dahlgaeen C, Entrei C. Propofol decreases random and chemotactic stimulated locomotion of human neutrophils in vitro. Br J Anaesth 1993; 70:99-100.
28. O’Donnell NG, McSharry V, Wilkinson PC, Asbury AJ. Comparison of the inhibitory effects of propofol, thiopentone and midazolam on neutrophil polarisation in vitro in the presence or absence of human serum albumin. Br J Anaesth 1992; 69:70-74.
29. Heine J, Leuuer K, Scheinichen D, Ansenier L, Taeger K, Piepenbrock S. Flow cytometry evaluation of the in vitro influence of IV anaesthetics in respiratory burst of neutrophils. Br J Anaesth 1996; 77: 387-390.
30. Salo M, Pirttikangas C-O, Pulkki K. Effects of propofol emulsion and thiopentone on T1 helper cell type 1=type 2 balance in vitro. Anaesthesia 1997; 52: 341-344.
31. Heller A, Heller S, Belacrkken SA, Urbanschek R, Koch T. Effects of intravenous anaesthetics in bacterial elimination in human blood in vitro. Acta Anaesthesiol Scand 1998; 42:518-526.
32. Correa-Sales C, Tosta CE, Rizzo W. The effects of anaesthesia with thiopentone on T lymphocyte responses to antigen and mitogens in vivo and in vitro. Int J Immunopharmacol 1997; 192:117-128.
33. Braun SR, Lain AB, Clark KL. Role of corticosteroids in the development of pneumonia in mechanically ventilated head trauma victims. Crit Care Med 1986; 14:198-201.
34. Watt I, Ledingham I. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984; 39:973-981.
35. Beilin B, Shant Y, Hart J. Effects of anaesthesia based on large vs. small doses of fentanyl on NK cell cytotoxicity in the perioperative period. Anaesth Analg 1996; 82:492-497.
36. Yeager MP, Colacehio T, Yu CT. Morphine inhibits spontaneous and cytokine enhanced NK cell cytotoxicity in volunteers. Anaesthesiology 1995; 83:50-58.
37. McBride WI, Armstrong WA, Crockford AD. Selective reduction in leucocyte antigen expression after high dose fentanyl administration at cardiac surgery. Br J Anaesth 1994; 73:717-718.
38. Morgan EL. Regulation of human B lymphocyte activation by opioid peptide hormones. Inhibition of IgG production by opioid receptor class (mu-, kappaand delta-) selective antagonists. J Neuroimmunol 1996; 65:21-30.
39. Nair MP, Schwarts SA, Polasani R, Hou J, Sweet A, Chadna KC. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997; 4:127-132.
40. Di Francesco P, Gazino R, Casalinuovo IA, Palamaro AT, Favalli C, Graci E. Antifungal and immunoadjuvant properties of fluconazole in mice immunosuppressed with morphine. Chemotherapy 1997; 43:198-203.
41. Bidri M, Royer B, Averlant G, Bismuth G, Guillosson JJ, Aroa M. Inhibition of mouse mast cell proliferation and pro-inflammatory mediator release by benzodiazepines. Immunopharmacology 1999; 43:75-86.
42. Helmy SA, Al-Attiyah RJ. The immunomodulatary effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients. Anaesthesia 2001; 56:4-8.
43. Afessa B, Tefferi A, Hoagland HC. Outcome of recipients of BMT who require ICU support. Mayo Clin Proc. 1992; 67:117-122.
44. Groeger JS, White P Jr., Nierman DM. Multicentre outcome of cancer patients admitted to the ICU. A probability of mortality model. J Clin Oncol 1998; 16: 761-770.
45. Hauser MJ, Tosak J, Baler H. Survival of patients with cancer in a medical critical care unit. Arch Intern Med 1982; 142:527-529.
46. Dragsted L, Qrist J. Outcome from intensive care. A 5-year study of 1308 patients: Methodology and patient population. Eur J Anaesthesiol 1989; 6:23-27.
47. Moore FA, Feliciano DV, Andrassy RJ. Early enteral feeding compared with parenteral reduces postoperative septic complications. The results of a meta-analysis. Ann Surg 1991; 216:172-183.
48. Kudsk KA, Croce MA, Fabian TC, Tolley EA, Poret HA, Kuhl MR, Brown RO. Enteral versus parenteral feeding: Effects on septic morbidity after blunt and penetration abdominal trauma. Ann Surg 1992; 215:503-513.
49. Rivadeneira DE, Evoy D, Fahey TJ, et al. Nutritional support of the cancer patient. Cancer J Clin 1998; 48: 69-80.
50. Scouba WW. Nutritional support. N Engl J Med 1997; 336:41-48.
51. Klein S, Kinney J, Jeejeeboy K. Nutritional support in clinical practice. Review of published data and recommendation for future research directions. Am J Clin Nutr 1997; 66:683-706.
52. Heys SD, Gough DB, Khan L, Eremin O. Nutritional pharmacology and malignant disease: A therapeutic modality in patients with cancer? Br J Surg 1996; 83:608-619.
53. Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: A meta-analysis of randomised controlled clinical trials. Ann Surg 1999; 229:467-477.
54. Wilmore DG. The effect of Glutamine supplementation in patients following elective surgery and accidental surgery. J Nutr 2001; 131:2543S-2584S.
55. Ziegler TR. Glutamine supplementation in cancer patients receiving BMT and high dose chemotherapy. J Nutr 2001; 131:2578S-2584S.
56. Winston DJ, Emmanouilides C, Busuttil RW. Infection in liver transplant recipients. Clin Infect Dis 1995; 21:1077-1089.
57. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55:259-268.
58. Sable CA, Donowitz GR. Infections in BMT recipients. Clin Infect Dis 1994; 18:273-281.
59. Masur H, Cheigh JS, Stubenbord WT. Infection following renal transplantation: A changing pattern. Rev Infect Dis 1982; 4:1208-1219.
60. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469.
61. Parillo JE. The pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1478.
62. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1186 episodes of gram-negative bacteremia in a nonuniversity hospital. The effects of antimicrobial therapy. Rev Infect Med 1983; 5:629-638.
63. Engel A, Mack E, Kern P, Kern WV. An analysis of IL-8, IL-6 and CRP serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic patients. Infection 1998; 26:213-221.
64. De Bont ES, Vellenga E, Swaanenburg JL, Fiddler V, Viser-vaan Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicemia among cancer patients with fever and neutropenia. Br J Haematol 1999; 107:375-380.
65. Lehrnbecher T, Venzon D, de Hass M, Channock SJ, Kuhl J. Assessment of measuring circulating levels of IL-6, IL-8, CRP, soluble Fc gamma receptor type III and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999; 29:414-419.
66. Hughes WT, Armstrong D, Bodey G, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC. From the infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-396.
67. Bosi A, Laszlo D, Bacci S, Fanci R, Guidi S, Saccardi R, Vannucchi AM, Rossi-Ferrini P. An open evaluation of triple antibiotic therapy including vancomycin for febrile BMT recipients with severe neutropenia. J Chemother 1999; 11:287-292.
68. Wilson APR. Emerging antimicrobial resistance in the surgical compromised host. J Chemother 1999; 11: 518-523.
69. Rolston KV, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996; 42:348-353.
70. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinopristin = dalfopristin). Clin Infect Dis 2000; 30:403-404.
71. Glaspy JA. Hematologic supportive care of the critically ill cancer patients. Semin Oncol 2000; 27:375-383.
72. American Society of Clinical Oncology. Recommendations for the use of haemopoietic colony-stimulating factors: Evidence based, clinical practice guidelines. J Clin Oncol 1994; 12:2471-2508.
73. Bernard GR, Vincent JL, Latere PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
74. Gilles H, Gruson D, Vargas F, Valcitiono P, Gbikpi-Benissar G, Michael R, Cardinaud JP. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever and acute respiratory failure. N Engl J Med 2001; 344:481-487.
75. Baerg J, Murphy JJ, Anderson R, Maggey JF. Neutropenic enteropathy: A 10-year review. J Pediatr Surg 1999; 34:1068-1071.
76. Boggio L, Pooley R, Roth SI, Winter JN. Typhlitis complicating autologous blood stem cell transplantation for breast cancer. Bone Marrow Transplant 2000; 25:321-326.
77. Kunkel JM, Rosenthal D. Management of ileocaecal syndrome. Dis Colon Rectum 1985; 29:196-199.
78. Katz JA, Wagner ML, Goesik MV. Typhlitis: An 18-year experience and postmortem review. Cancer 1990; 65:1041-1047.
79. Wade DS, Nava HR, Douglass HO Jr. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 1992; 69:17-23.
80. Hanada T, Ono I, Hirano C, Kurosaki Y. Successful treatment of neutropenic enterocolitis with recombinant granulocyte stimulating factors in a child with ALL. Eur J Pediatr 1990; 149:811-812.
81. Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med 1984; 77:20-27.
82. Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Systemic candidiasis in patients with acute leukaemia. Br J Haematol 1999; 106:697-701.
83. Goldman D, Larson E. Hand washing and nosocomial infection. N Engl J Med 1992; 327:120-122.
84. Voss A, Widmer AF. No time for handwashing? Handwashing versus alcoholic rub; can we afford 100% compliance? Infect Control Hosp Epidemiol 1997; 18:205-208.
85. Pizzo PA. The value of protective isolation in preventing nosocomial infections in high risk patients. Am J Med 1981; 70:631-637.
86. Heyland DK, Cook DJ, Jaeschke R, et al. Selective decontamination of the digestive tract: An overview. Chest 1994; 105:1221-1229.
87. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: A systematic review of the evidence. Arch Surg 1999; 134:170-176.
88. Ramsay G, Van Saene RH. Selective gut decontamination in intensive care and surgical practice: where are we? World J Surg 1998; 22:164-170.
89. Kollef MH. The role of selective digestive decontamination on mortality and respiratory tract infections: A meta analysis. Chest 1994; 105:1101-1108.
90. Emre S, Sebastian A, Chodoff L, et al. Selective decontamination of the digestive tract helps prevent bacterial infections in the early postoperative period after liver transplant. Mt Sinai J Med 1999; 66:310-313.
91. Silvestri L, Mannucci F, Van Saene HK. Selective decontamination of the digestive tract: A lifesaver. J Hosp Infect 2000; 45:185-190.
92. Howard EJ, Simmons RL. Acquired immunologic deficiencies after trauma and surgical procedures. Surg Gynecol Obst 1974; 139:771-777.
93. Nelson CJ, Lysle DT. Severity, time and B-adrenergic receptor involvement in surgery-induced immune alterations. J Surg Res 1998; 80:115-122.
94. Luecken L, Lysle DT. Evidence for the involvement of B-adrenergic receptors in conditional immunomodulation. J Neuroimmunol 1992; 38:209-219.
95. Constantian MB, Menzoian JO, Nimberg RB, Schmid K, Mannick JA. Association of a circulating immunosuppressive polypeptide with operative and accidental trauma. Ann Surg 1976; 185:73-79.
96. Lefor AT. Perioperative management of the patient with the cancer. Chest 1999; 115:165S-171S.
97. McBride WT, Armstrong MA, McBride SJ. Immunomodulation: An important concept in anaesthesia. Anaesthesia 1996; 51:465-473.
98. Wong PW, Enriquez A, Barrera R. Nutritional support in critically ill patients with cancer. Critical Care Clin 2001; 17:743-767.
99. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001; 17:531-570.
100. Heys SD, Gough DB, Khan L, Eremin O. Nutritional pharmacology and malignant disease: A therapeutic modality in patients with cancer. Br J Surg 1996; 83:608-619.